BACKGROUND: Outcomes in patients with chronic myeloid leukemia in blast phase (CML-BP) are historically dismal. Herein, the authors sought to analyze the characteristics, prognostic factors, and survival outcomes in patients with CML-BP in the tyrosine kinase inhibitor (TKI) era. METHODS: A total of 477 patients with CML-BP were treated with a TKI at some point during the course of their CML. Cox proportional hazard models identified characteristics that were predictive of survival. Overall survival and failure-free survival were assessed. Optimal cutoff points for specific parameters were identified using classification and regression tree (CART) analysis. RESULTS: The median age of the patients was 53 years (range, 16-84 years) and 64% were male. Approximately 80% of patients initially were diagnosed in the chronic phase of CML at a median of 41 months (range, 0.7-298 months) before transformation to CML-BP. De novo CML-BP occurred in 71 patients. Approximately 72% of patients received TKI therapy before CML-BP. The initial therapy for CML-BP included a TKI alone (35%), a TKI with chemotherapy (46%), and non-TKI therapies (19%). The median overall survival was 12 months and the median failure-free survival was 5 months. In multivariate analysis, myeloid immunophenotype, prior TKI, age ≥58 years, lactate dehydrogenase level ≥1227 IU/L, platelet count < 102 K/μL, no history of stem cell transplantation, transition to BP from chronic phase/accelerated phase, and the presence of chromosome 15 aberrations predicted for a significantly increased risk of death. Achievement of major hematologic response and/or complete cytogenetic response to first-line treatment was found to be predictive of better survival. The combination of a TKI with intensive chemotherapy followed by stem cell transplantation appeared to confer the best outcome. CONCLUSIONS: Patients with CML-BP continue to pose a therapeutic challenge, have dismal outcomes, and require newer treatment approaches. Cancer 2017;123:4391-402.
BACKGROUND: Outcomes in patients with chronic myeloid leukemia in blast phase (CML-BP) are historically dismal. Herein, the authors sought to analyze the characteristics, prognostic factors, and survival outcomes in patients with CML-BP in the tyrosine kinase inhibitor (TKI) era. METHODS: A total of 477 patients with CML-BP were treated with a TKI at some point during the course of their CML. Cox proportional hazard models identified characteristics that were predictive of survival. Overall survival and failure-free survival were assessed. Optimal cutoff points for specific parameters were identified using classification and regression tree (CART) analysis. RESULTS: The median age of the patients was 53 years (range, 16-84 years) and 64% were male. Approximately 80% of patients initially were diagnosed in the chronic phase of CML at a median of 41 months (range, 0.7-298 months) before transformation to CML-BP. De novo CML-BP occurred in 71 patients. Approximately 72% of patients received TKI therapy before CML-BP. The initial therapy for CML-BP included a TKI alone (35%), a TKI with chemotherapy (46%), and non-TKI therapies (19%). The median overall survival was 12 months and the median failure-free survival was 5 months. In multivariate analysis, myeloid immunophenotype, prior TKI, age ≥58 years, lactate dehydrogenase level ≥1227 IU/L, platelet count < 102 K/μL, no history of stem cell transplantation, transition to BP from chronic phase/accelerated phase, and the presence of chromosome 15 aberrations predicted for a significantly increased risk of death. Achievement of major hematologic response and/or complete cytogenetic response to first-line treatment was found to be predictive of better survival. The combination of a TKI with intensive chemotherapy followed by stem cell transplantation appeared to confer the best outcome. CONCLUSIONS:Patients with CML-BP continue to pose a therapeutic challenge, have dismal outcomes, and require newer treatment approaches. Cancer 2017;123:4391-402.
Authors: V S Hoffmann; M Baccarani; J Hasford; D Lindoerfer; S Burgstaller; D Sertic; P Costeas; J Mayer; K Indrak; H Everaus; P Koskenvesa; J Guilhot; G Schubert-Fritschle; F Castagnetti; F Di Raimondo; S Lejniece; L Griskevicius; N Thielen; T Sacha; A Hellmann; A G Turkina; A Zaritskey; A Bogdanovic; Z Sninska; I Zupan; J-L Steegmann; B Simonsson; R E Clark; A Covelli; G Guidi; R Hehlmann Journal: Leukemia Date: 2015-03-18 Impact factor: 11.528
Authors: Paolo Strati; Hagop Kantarjian; Deborah Thomas; Susan O'Brien; Sergej Konoplev; Jeffrey L Jorgensen; Raja Luthra; Lynne Abruzzo; Elias Jabbour; Alfonso Quintas-Cardama; Gautam Borthakur; Stefan Faderl; Farhad Ravandi; Jorge Cortes Journal: Cancer Date: 2013-10-22 Impact factor: 6.860
Authors: Susanne Saussele; Michael Lauseker; Alois Gratwohl; Dietrich W Beelen; Donald Bunjes; Rainer Schwerdtfeger; Hans-Jochem Kolb; Anthony D Ho; Christiane Falge; Ernst Holler; Günter Schlimok; Axel R Zander; Renate Arnold; Lothar Kanz; Robert Dengler; Claudia Haferlach; Brigitte Schlegelberger; Markus Pfirrmann; Martin C Müller; Susanne Schnittger; Armin Leitner; Nadine Pletsch; Andreas Hochhaus; Joerg Hasford; Rüdiger Hehlmann Journal: Blood Date: 2009-11-18 Impact factor: 22.113
Authors: Bing Z Carter; Po Yee Mak; Hong Mu; Hongsheng Zhou; Duncan H Mak; Wendy Schober; Joel D Leverson; Bin Zhang; Ravi Bhatia; Xuelin Huang; Jorge Cortes; Hagop Kantarjian; Marina Konopleva; Michael Andreeff Journal: Sci Transl Med Date: 2016-09-07 Impact factor: 17.956
Authors: M Schmidt; J Rinke; V Schäfer; S Schnittger; A Kohlmann; E Obstfelder; C Kunert; J Ziermann; N Winkelmann; E Eigendorff; T Haferlach; C Haferlach; A Hochhaus; T Ernst Journal: Leukemia Date: 2014-09-12 Impact factor: 11.528
Authors: Wei Wang; Jorge E Cortes; Guilin Tang; Joseph D Khoury; Sa Wang; Carlos E Bueso-Ramos; Joseph A DiGiuseppe; Zi Chen; Hagop M Kantarjian; L Jeffrey Medeiros; Shimin Hu Journal: Blood Date: 2016-03-22 Impact factor: 22.113
Authors: Abhishek Maiti; Miguel J Franquiz; Farhad Ravandi; Jorge E Cortes; Elias J Jabbour; Koji Sasaki; Kayleigh Marx; Naval G Daver; Tapan M Kadia; Marina Y Konopleva; Lucia Masarova; Gautam Borthakur; Courtney D DiNardo; Kiran Naqvi; Sherry Pierce; Hagop M Kantarjian; Nicholas J Short Journal: Acta Haematol Date: 2020-04-14 Impact factor: 2.195